Ignite Creation Date:
2025-12-25 @ 4:57 AM
Ignite Modification Date:
2025-12-26 @ 3:57 AM
Study NCT ID:
NCT03492918
Status:
UNKNOWN
Last Update Posted:
2022-03-15
First Post:
2018-04-01
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16)
Sponsor:
Yonsei University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-04
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-04
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-05
Completion Date Type:
ESTIMATED
First Submit Date:
2018-04-01
First Submit QC Date:
None
Study First Post Date:
2018-04-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-03-14
Last Update Post Date:
2022-03-15
Last Update Post Date Type:
ACTUAL